Search hospitals > Oklahoma > Oklahoma City

Oklahoma Medical Research Foundation

Claim this profile
Oklahoma City, Oklahoma 73104
Global Leader in Systemic Lupus Erythematosus
Global Leader in Lupus
Conducts research for Multiple Sclerosis
Conducts research for Coronary Artery Disease
Conducts research for Rheumatoid Arthritis
154 reported clinical trials
6 medical researchers
Photo of Oklahoma Medical Research Foundation in Oklahoma CityPhoto of Oklahoma Medical Research Foundation in Oklahoma City

Summary

Oklahoma Medical Research Foundation is a medical facility located in Oklahoma City, Oklahoma. This center is recognized for care of Systemic Lupus Erythematosus, Lupus, Multiple Sclerosis, Coronary Artery Disease, Rheumatoid Arthritis and other specialties. Oklahoma Medical Research Foundation is involved with conducting 154 clinical trials across 111 conditions. There are 6 research doctors associated with this hospital, such as Gabriel Pardo, Cristina Arriens, MD, MSCS, Judith A. James, MD, PhD, and Christina Arriens, MD.

Area of expertise

1Systemic Lupus Erythematosus
Global Leader
Oklahoma Medical Research Foundation has run 38 trials for Systemic Lupus Erythematosus. Some of their research focus areas include:
ANA positive
anti-dsDNA positive
anti-Sm positive
2Lupus
Global Leader
Oklahoma Medical Research Foundation has run 31 trials for Lupus. Some of their research focus areas include:
ANA positive
dsDNA positive
anti-dsDNA positive

Top PIs

Clinical Trials running at Oklahoma Medical Research Foundation

Multiple Sclerosis
Lupus
Systemic Lupus Erythematosus
Shingles
Neuromyelitis Optica (NMO)
Nephritis
Lupus Nephritis
Image of trial facility.

Ocrelizumab

for Multiple Sclerosis

This study is a prospective, multi-center, randomized, double blinded, placebo-controlled study of OCR treatment-discontinuation in patients with early RMS. All eligible participants will be initiated on OCR using the standard approved administration schedule of two 300 mg infusions separated by 14 days (i.e., Days 0 and 14) for a total of 600 mg, followed by 600 mg infusions at Month 6 and Month 12. At Month 12, participants will be randomized (1:1:1) to one of three Arms with randomized treatment beginning at Month 18: Arm 1: placebo infusions every 6 months; Arm 2: OCR infusions at Months 18 and 24 and then after Month 24 switch to placebo infusions every 6 months; Arm 3: OCR infusions every 6 months. The treatment period will be for a total of 48 months.
Recruiting2 awards Phase 4
Image of trial facility.

MSCopilot® App

for Multiple Sclerosis

The study aims to evaluate MSCopilot® Detect, a smartphone application for at-home monitoring of patients with Multiple Sclerosis (MS). The primary objective is to enhance and standardize remote monitoring of MS patients to accurately assess disease progression caused by either Relapse Activity Worsening (RAW) or Progression Independent of Relapses (PIRA). The study also aims to assess the safety, usability, and satisfaction of the solution. A secondary objective is to determine MSCopilot® Detect's ability to provide early detection of disease changes and predict changes in Expanded Disability Status Scale (EDSS) scores in more patients. Exploratory objectives include evaluating the relationship between MSCopilot® Detect composite and individual scores and other biomarkers such as MRI, soluble glial fibrillary acidic protein (sGFAP), and soluble neurofilament light chain (sNfL). Patients will be able to download the free MSCopilot® Detect app. They will participate in 1 inclusion visit and 3 follow-up visits, scheduled at 6 months, 12 months, and 18 months (an additional visit at 24 months may be scheduled if necessary). Every 3 months, patients will complete validated questionnaires regarding MS symptoms and quality of life and participate in digital tests designed to monitor MS symptom progression. The study will include 314 MS patients and will be conducted in the United States, Canada, Germany, Italy, Spain, Denmark and France
Recruiting1 award N/A
Image of trial facility.

Early Aggressive vs Traditional Therapy

for Multiple Sclerosis

Recruiting1 award N/A5 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Oklahoma Medical Research Foundation?
Oklahoma Medical Research Foundation is a medical facility located in Oklahoma City, Oklahoma. This center is recognized for care of Systemic Lupus Erythematosus, Lupus, Multiple Sclerosis, Coronary Artery Disease, Rheumatoid Arthritis and other specialties. Oklahoma Medical Research Foundation is involved with conducting 154 clinical trials across 111 conditions. There are 6 research doctors associated with this hospital, such as Gabriel Pardo, Cristina Arriens, MD, MSCS, Judith A. James, MD, PhD, and Christina Arriens, MD.